公开(公告)号：US11530213B2

公开(公告)日：2022-12-20

申请号：US17071311

申请日：2020-10-15

Applicant: NOVARTIS AG

Inventor： Guillaume Barbe ,  Gregory Raymond Bebernitz ,  Sicong Geng ,  Hatice Belgin Gulgeze Efthymiou ,  Lv Liao ,  Fupeng Ma ,  Ruowei Mo ,  David Thomas Parker ,  Yunshan Peng ,  Stefan Peukert ,  Nichola Smith ,  Ken Yamada ,  Kayo Yasoshima

IPC: A61P9/00 ,  A61P9/06 ,  C07D471/04 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/675 ,  A61K45/06 ,  C07F9/6561

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US11427586B2

公开(公告)日：2022-08-30

申请号：US17101510

申请日：2020-11-23

Applicant: NOVARTIS AG

Inventor： Kelly D. Boss ,  Yi Fan ,  Alec Nathanson Flyer ,  Declan Hardy ,  Zhihong Huang ,  Kathryn Taylor Linkens ,  Jon Christopher Loren ,  Fupeng Ma ,  Valentina Molteni ,  Duncan Shaw ,  Jeffrey Smith ,  Catherine Fooks Solovay

IPC: C07D471/10 ,  C07D413/14 ,  C07D491/107 ,  C07D413/06 ,  A61P27/04

Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I′), or pharmaceutical composition described herein.

公开(公告)号：US11185537B2

公开(公告)日：2021-11-30

申请号：US16504376

申请日：2019-07-08

Applicant: Novartis AG

Inventor： Rohan Eric John Beckwith ,  Simone Bonazzi ,  Artiom Cernijenko ,  Fupeng Ma ,  Nathaniel F. Ware

IPC: C07D401/14 ,  A61K31/454 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/498 ,  C07D401/04

Abstract: The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.

公开(公告)号：US11833142B2

公开(公告)日：2023-12-05

申请号：US17493055

申请日：2021-10-04

Applicant: Novartis AG

Inventor： Rohan Eric John Beckwith ,  Simone Bonazzi ,  Artiom Cernijenko ,  Fupeng Ma ,  Nathaniel F. Ware

IPC: A61K31/454 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/498 ,  C07D401/04 ,  C07D401/14

CPC classification number: A61K31/454 ,  A61K31/4545 ,  A61K31/498 ,  A61P35/00 ,  C07D401/04 ,  C07D401/14

Abstract: The present disclosure provides a compound of Formula (I′):






or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.

公开(公告)号：US10266531B2

公开(公告)日：2019-04-23

申请号：US15788248

申请日：2017-10-19

Applicant: NOVARTIS AG

Inventor： Guillaume Barbe ,  Gregory Raymond Bebernitz ,  Sicong Geng ,  Hatice Belgin Gulgeze Efthymiou ,  Lv Liao ,  Fupeng Ma ,  Ruowei Mo ,  David Thomas Parker ,  Yunshan Peng ,  Stefan Peukert ,  Ken Yamada ,  Kayo Yasoshima

IPC: C07D487/04 ,  C07D471/04 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/675 ,  A61K45/06 ,  C07F9/6561 ,  A61P9/06

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.